Location:
Kardinal Wendel Haus
Mandlstrasse 23, 80802 Munich

Day 3: THURSDAY, 17th

09:00 – 09:45  Plenary Speech

               Genetics of Small Vessel Disease: Discovery, Biology and Clinical Applications

               Martin Dichgans, LMU Hospital, Institute for Stroke and Dementia Research, Munich,                  Germany

09:45 – 10:20  Selected Oral Abstracts 

               Chair: Martin Dichgans, LMU Hospital, Institute for Stroke and Dementia Research,                    Munich, Germany               

               
               Pericyte remodeling deficits in CAA lead to uncovered postcapillary venules

               Cara Nielson, University of Washington, Seattle, USA

               Single ascending dose results from an ongoing Phase 1 study of mivelsiran for                    Alzheimer’s disease

               Robert Deering, Alnylam Pharmaceuticals, Cambridge, MA, USA

               AB1601 phase 2 study of ABvac40, an anti-Aβ40 vaccine: results in a-MCI and vm-                AD patients and potential impact on CAA

               María Montañés, Araclon Biotech-Grifols, Zaragoza, Spain

10:20 – 10:50  Coffee break

 
10:50 – 12:30  Session 7 – ICAAA Guidelines for CAA 

               Chair: Steve Greenberg, Massachusetts General Hospital / Harvard Medical School,                    Boston, USA

10:50 – 11:10  Diagnosis, testing, and risk prediction

               Eric Smith, University of Calgary, Alberta, Canada

11:10 – 11:30   Treatments/interventions: use of antithrombotic agents

               Karin Klijn, Radboud University Medical Center, Nijmegen, The Netherlands

11:30 – 11:50  Treatments/interventions: blood pressure, other medications, lifestyle

               Charlotte Cordonnier, Lille University Hospital, France

11:50 – 12:10  Treatment of CAA manifestations
               Andreas Charidimou, Boston University Medical Center, USA

12:10 – 12:30  Diagnosis and treatment of CAA-ri

               David Werring, University College London, UK

12:30 – 14:00  Lunch & Poster viewing

14:00 – 15:30  Session 8: What are the next intervention trials for CAA? 

               Chair: Mark van Buchem, Leiden University Medical Center, The Netherlands

14:00 – 14:25  Interventions targeting APP expression

               Neal Parikh, Alnylam Pharmaceuticals, Cambridge MA, USA

14:25 – 14:50  Medin as a treatment target in CAA and AD

              Jonas Neher, DZNE, Munich, Germany

14:50 – 15:15  Interventions targeting vessel remodeling/inflammation

               Marieke Wermer, University Medical Center Groningen, The Netherlands

15:15 – 15:45  ICAAA update & Official Conference Closure

               Steven Greenberg, Chair ICAA Association